Patents Assigned to ALCRESTA THERAPEUTICS, INC.
-
Patent number: 11944596Abstract: Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.Type: GrantFiled: May 27, 2021Date of Patent: April 2, 2024Assignee: Alcresta Therapeutics, Inc.Inventors: Robert Gallotto, Greta L. Loring, Kenneth Gary, Edward S. Park, David J. Brown, Willem Robert Klaas Schoevaart, Michiel Christian Alexander van Vliet
-
Publication number: 20240065943Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monogiycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.Type: ApplicationFiled: November 6, 2023Publication date: February 29, 2024Applicant: Alcresta Therapeutics, Inc.Inventors: Alexey L. MARGOLIN, Robert GALLOTTO, Bhami SHENOY
-
Patent number: 11911357Abstract: Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.Type: GrantFiled: May 27, 2021Date of Patent: February 27, 2024Assignee: Alcresta Therapeutics, Inc.Inventors: Robert Gallotto, Greta L. Loring, Kenneth Gary, Edward S. Park, David J. Brown, Willem Robert Klaas Schoevaart, Michiel Christian Alexander van Vliet
-
Patent number: 11872191Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.Type: GrantFiled: March 24, 2021Date of Patent: January 16, 2024Assignee: Alcresta Therapeutics, Inc.Inventors: Alexey L. Margolin, Robert Gallotto, Bhami Shenoy
-
Publication number: 20230014170Abstract: Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other.Type: ApplicationFiled: September 20, 2022Publication date: January 19, 2023Applicant: Alcresta Therapeutics, Inc.Inventors: Eric First, David Widom
-
Patent number: 11478431Abstract: Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other.Type: GrantFiled: June 16, 2020Date of Patent: October 25, 2022Assignee: Alcresta Therapeutics, Inc.Inventors: Eric First, David Widom
-
Publication number: 20220331208Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.Type: ApplicationFiled: June 29, 2022Publication date: October 20, 2022Applicant: Alcresta Therapeutics, IncInventors: Alexey L. MARGOLIN, Robert GALLOTTO, Bhami SHENOY
-
Publication number: 20220331206Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.Type: ApplicationFiled: June 29, 2022Publication date: October 20, 2022Applicant: Alcresta Therapeutics, Inc.Inventors: Alexey L. MARGOLIN, Robert GALLOTTO, Bhami SHENOY
-
Publication number: 20220331207Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.Type: ApplicationFiled: June 29, 2022Publication date: October 20, 2022Applicant: Alcresta Therapeutics, Inc.Inventors: Alexey L. MARGOLIN, Robert GALLOTTO, Bhami SHENOY
-
Publication number: 20220264926Abstract: Exemplary embodiments of the disclosure may be drawn to a device having an inlet and a chamber. Immobilized lipase, immobilized protease, and immobilized amylase may be contained within the chamber. The device may also include an outlet, wherein a flow path extends from the inlet, through the chamber, and to the outlet.Type: ApplicationFiled: March 1, 2022Publication date: August 25, 2022Applicant: Alcresta Therapeutics, Inc.Inventors: Eric FIRST, David BROWN, Albert Archie STONE
-
Patent number: 11291236Abstract: Exemplary embodiments of the disclosure may be drawn to a device having an inlet and a chamber. Immobilized lipase, immobilized protease, and immobilized amylase may be contained within the chamber. The device may also include an outlet, wherein a flow path extends from the inlet, through the chamber, and to the outlet.Type: GrantFiled: September 6, 2018Date of Patent: April 5, 2022Assignee: Alcresta Therapeutics, Inc.Inventors: Eric First, David Brown, Albert Archie Stone
-
Publication number: 20210283085Abstract: Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.Type: ApplicationFiled: May 27, 2021Publication date: September 16, 2021Applicant: Alcresta Therapeutics, Inc.Inventors: Robert GALLOTTO, Greta L. LORING, Kenneth GARY, Edward S. PARK, David J. BROWN, Willem Robert Klaas SCHOEVAART, Michiel Christian Alexander van VLIET
-
Publication number: 20210259924Abstract: Exemplary embodiments of the disclosure may be drawn to a device having a vessel configured to contain a source of lipids and a chamber fluidly connected to an outlet of the vessel. The chamber may contain immobilized lipase positioned within a flow path in the chamber along which the lipids flow when released from the vessel into the chamber. The device may also include an outlet through which the lipids flow after passing through the chamber.Type: ApplicationFiled: May 11, 2021Publication date: August 26, 2021Applicant: Alcresta Therapeutics, Inc.Inventors: Eric FIRST, David Widom
-
Publication number: 20210212904Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monogiycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.Type: ApplicationFiled: March 24, 2021Publication date: July 15, 2021Applicant: Alcresta Therapeutics, Inc.Inventors: Alexey L. Margolin, Robert Gallotto, Bhami Shenoy
-
Patent number: 11045440Abstract: Embodiments of the disclosure are drawn to an enteral feeding device for hydrolyzing triglycerides in a nutritional formula. The device may include a body housing a chamber, an inlet configured to fluidly couple with a source of nutritional formula, and an outlet configured to fluidly couple with an enteral feeding tube. The device may include a headspace and a plurality of particles contained within the chamber, wherein the lipase is covalently bonded to the plurality of particles. The device may include an inlet filter located between the inlet and the chamber, wherein the inlet filter contains a first plurality of openings, and an outlet filter located between the chamber and the outlet, wherein the outlet filter has a second plurality of openings smaller than the plurality of particles.Type: GrantFiled: February 27, 2019Date of Patent: June 29, 2021Assignee: Alcresta Therapeutics, Inc.Inventors: Robert Gallotto, Greta L. Loring, Kenneth Gary, Edward S. Park, David J. Brown, Willem Robert Klaas Schoevaart, Michiel Christian Alexander van Vliet
-
Patent number: 11045396Abstract: Exemplary embodiments of the disclosure may be drawn to a device having a vessel configured to contain a source of lipids and a chamber fluidly connected to an outlet of the vessel. The chamber may contain immobilized lipase positioned within a flow path in the chamber along which the lipids flow when released from the vessel into the chamber. The device may also include an outlet through which the lipids flow after passing through the chamber.Type: GrantFiled: August 15, 2018Date of Patent: June 29, 2021Assignee: Alcresta Therapeutics, Inc.Inventors: Eric First, David Widom
-
Patent number: 10987280Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.Type: GrantFiled: June 5, 2018Date of Patent: April 27, 2021Assignee: Alcresta Therapeutics, Inc.Inventors: Alexey L. Margolin, Robert Gallotto, Bhami Shenoy
-
Patent number: 10828239Abstract: Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monogiycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.Type: GrantFiled: May 23, 2018Date of Patent: November 10, 2020Assignee: Alcresta Therapeutics, Inc.Inventors: Alexey L. Margolin, Robert Gallotto, Bhami Shenoy
-
Publication number: 20200306196Abstract: Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other.Type: ApplicationFiled: June 16, 2020Publication date: October 1, 2020Applicant: Alcresta Therapeutics, Inc.Inventors: Eric First, David Widom
-
Patent number: 10716761Abstract: Exemplary embodiments of the disclosure may be drawn to ingestible delivery devices. An ingestible delivery device may include a first compartment and a second compartment. A lipase may be contained within the first compartment, and a fat may be contained within the second compartment. The first compartment may be sealed from the second compartment prior to exposure to a trigger, preventing the lipase and the fat from contacting each other, and at least one of the first compartment or the second compartment may at least partially rupture upon exposure to the trigger, allowing the lipase and the fat to contact each other.Type: GrantFiled: July 23, 2018Date of Patent: July 21, 2020Assignee: Alcresta Therapeutics, Inc.Inventors: Eric First, David Widom